Losoxantrone

Losoxantrone

SCHEMBL61319

O=C1c2c(O)cccc2-c2nn(CCNCCO)c3ccc(NCCNCCO)c1c23

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 10/20 1.00
MEN1 O00255 2/20 0.51
USP2 O75604 2/20 0.51
LMNA P02545 2/20 0.51
TP53 P04637 2/20 0.51
MAPK1 P28482 2/20 0.51
RECQL P46063 2/20 0.51
BLM P54132 2/20 0.51
KMT2A Q03164 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
NSD2 O96028 2/20 0.51
CSNK2A1 P68400 2/20 0.51
NPC1 O15118 1/20 0.51
SLC22A2 O15244 1/20 0.51
SLC22A1 O15245 1/20 0.51
CACNA1F O60840 1/20 0.51
SLC22A3 O75751 1/20 0.51
EGFR P00533 1/20 0.51
ESR1 P03372 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Losoxantrone SCHEMBL29360703 1.00 TOP2A (1.00) TOP2AMEN1USP2LMNATP53
Losoxantrone SCHEMBL29409658 0.99 TOP2A (0.98) TOP2AMEN1USP2LMNATP53
Losoxantrone SCHEMBL6685621 0.99 TOP2A (0.98) TOP2AMEN1USP2LMNATP53
Losoxantrone SCHEMBL5170 0.98 TOP2A (0.96) TOP2AMEN1USP2LMNATP53
SCHEMBL10800466 0.94 TOP2A (0.90) TOP2AMEN1USP2LMNATP53
SCHEMBL22877226 0.93 TOP2A (0.87) TOP2AMEN1USP2LMNATP53
SCHEMBL18689529 0.93 TOP2A (0.87) TOP2AMEN1USP2LMNATP53
SCHEMBL10805434 0.92 TOP2A (0.86) TOP2AMEN1USP2LMNATP53
SCHEMBL10801795 0.89 TOP2A (0.79) TOP2AMEN1USP2LMNATP53
SCHEMBL10803842 0.88 TOP2A (0.79) TOP2AMEN1USP2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 26739 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
WO-2026099502-A1 NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2026-05-15 WO claimed
EP-4737898-A2 SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE EMP Biotech GmbH (DE) 2026-05-06 EP claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
EP-4729063-A2 TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES BPGbio, Inc. (US) 2026-04-22 EP claimed
EP-4698185-A1 METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES Osasuna Therapeutics SA (CH) 2026-02-25 EP claimed
EP-4694909-A1 METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION RS Oncology, LLC (US) 2026-02-18 EP claimed
EP-4687999-A1 TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS OBI Pharma, Inc. (TW) 2026-02-11 EP claimed
EP-4676544-A1 ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODIES AGAINST HUMAN L1CAM AND USES THEREOF LigaChem Biosciences Inc. (KR) 2026-01-14 EP claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
WO-2001097789-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING ACRYLOYL DISTAMYCIN DERIVATIVES AND TOPOISOMERASE I AND II INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2001-12-27 WO claimed
US-20010027195-A1 Indeno [1,2-c]pyrazol-4-ones and their uses DUPONT PHARMACEUTICALS COMPANY 2001-10-04 US claimed
US-6291504-B1 POTENT INHIBITORS OF THE CLASS OF ENZYMES KNOWN AS CYCLIN DEPENDENT KINASES DUPONT PHARMACEUTICALS COMPANY 2001-09-18 US claimed
EP-1085891-A1 MULTIBINDING INHIBITORS OF TOPOISOMERASE Advanced Medicine, Inc. (US) 2001-03-28 EP claimed
WO-2001018013-A1 PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY METABASIS THERAPEUTICS, INC. (US) 2001-03-15 WO claimed
WO-2000069467-A1 COMBINED METHOD OF TREATMENT COMPRISING AN AROMATASE INHIBITOR AND A FURTHER BIOLOGICALLY ACTIVE COMPOUND PHARMACIA & UPJOHN S.P.A. (IT) 2000-11-23 WO claimed
WO-2000021565-A1 SELECTIVE ERADICATION OF VIRALLY-INFECTED CELLS BY COMBINED USE OF A CYTOTOXIC AGENT AND AN ANTIVIRAL AGENT DU PONT PHARMACEUTICALS COMPANY (US) 2000-04-20 WO claimed
WO-1999064054-A9 MULTIBINDING INHIBITORS OF TOPOISOMERASE ADVANCED MEDICINE INC (US) 2000-03-02 WO claimed
WO-1999064054-A1 MULTIBINDING INHIBITORS OF TOPOISOMERASE ADVANCED MEDICINE, INC. (US) 1999-12-16 WO claimed
EP-0103381-B1 SUBSTITUTED ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONES WARNER-LAMBERT COMPANY (US) 1987-09-23 EP claimed